A dynamic thermal ATR-FTIR/chemometric approach to the analysis of polymorphic interconversions. Cimetidine as a model drug

被引:31
作者
Calvo, Natalia L.
Maggio, Ruben M.
Kaufman, Teodoro S. [1 ]
机构
[1] Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Quim Organ, Area Anal Med, Rosario, Santa Fe, Argentina
关键词
Crystal polymorphism; Multivariate curve resolution with alternating least squares (MCR-ALS); Cimetidine; ATR-FTIR/chemometrics; Crystal form interconversion; MULTIVARIATE CURVE RESOLUTION; SOLID-STATE; FORMS; BIOAVAILABILITY; DISCRIMINATION; SPECTROSCOPY; MICROSCOPY; C10H16N6S; TABLETS; TOOL;
D O I
10.1016/j.jpba.2013.12.036
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Crystal polymorphism of active ingredients is relevant to the pharmaceutical industry, since polymorphic changes taking place during manufacture or storage of pharmaceutical formulations can affect critical properties of the products. Cimetidine (CIM) has several relevant solid state forms, including four polymorphs (A, B, C and D), an amorphous form (AM) and a monohydrate (M1). Dehydration of M1 has been reported to yield mixtures of polymorphs A, B and C or just a single form. Standards of the solid forms of CIM were prepared and unequivocally characterized by FTIR spectroscopy, digital microscopy, differential scanning calorimetry and solid state C-13 NMR spectroscopy. Multivariate curve resolution with alternating least squares (MCR-ALS) was coupled to variable temperature attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) to dynamically characterize the behavior of form M1 of CIM over a temperature range from ambient to 160 degrees C, without sample pretreatment. MCR-ALS analysis of ATR-FTIR spectra obtained from the tested solid under variable temperature conditions unveiled the pure spectra of the species involved in the polymorphic transitions. This allowed the simultaneous observation of thermochemical and thermophysical events associated to the changes involved in the solid forms, enabling their unequivocal identification and improving the understanding of their thermal behavior. It was demonstrated that under the experimental conditions, dehydration of M1 initially results in the formation of polymorph B; after melting and upon cooling, the latter yields an amorphous solid (AM). It was concluded that the ATR-FTIR/MCR association is a promising and useful technique for monitoring solid-state phase transformations. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:90 / 97
页数:8
相关论文
共 49 条
  • [1] Solid form screening - A review
    Aaltonen, Jaakko
    Alleso, Morten
    Mirza, Sabiruddin
    Koradia, Vishal
    Gordon, Keith C.
    Rantanen, Jukka
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 71 (01) : 23 - 37
  • [2] Cimetidine, C10H16N6S, form C: crystal structure and modelling of polytypes using the superspace approach
    Arakcheeva, Alla
    Pattison, Philip
    Bauer-Brandl, Annette
    Birkedal, Henrik
    Chapuis, Gervais
    [J]. JOURNAL OF APPLIED CRYSTALLOGRAPHY, 2013, 46 : 99 - 107
  • [3] FT-IR and FT-Raman spectra of cimetidine and its metallocomplexes
    Baranska, M
    Proniewicz, LM
    [J]. JOURNAL OF MOLECULAR STRUCTURE, 1999, 511 : 153 - 162
  • [4] Ritonavir: An extraordinary example of conformational polymorphism
    Bauer, J
    Spanton, S
    Henry, R
    Quick, J
    Dziki, W
    Porter, W
    Morris, J
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (06) : 859 - 866
  • [5] Comparison of experimental methods and theoretical calculations on crystal energies of 'isoenergetic' polymorphs of cimetidine
    Bauer-Brandl, A
    Marti, E
    Geoffroy, A
    Poso, A
    Suurkuusk, J
    Wappler, E
    Bauer, KH
    [J]. JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 1999, 57 (01): : 7 - 22
  • [6] Polymorphic transitions of cimetidine during manufacture of solid dosage forms
    BauerBrandl, A
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 140 (02) : 195 - 206
  • [7] Bencsik P., 1992, Novel cimetidine polymorph and process for preparing same, Patent No. [WO 92/14713, 9214713]
  • [8] Bernstein J., 2002, POLYMORPHISM MOL CRY, V73, P255
  • [9] Birkedal H., 2000, 19 19 EUR CRYST M AU
  • [10] Brittain H.G., 2009, Polymorphism in Pharmaceutical Solids